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Background: Radiation induced transcriptional targeting is a gene therapy approach that takes advantage of the
targeting abilities of radiotherapy by using radio inducible promoters to spatially and temporally limit the transgene
expression. Cyclin dependent kinase inhibitor 1 (CDKN1A), also known as p21, is a crucial regulator of the cell cycle,
mediating G1 phase arrest in response to a variety of stress stimuli, including DNA damaging agents like irradiation.
The aim of the study was to evaluate the suitability of the p21 promoter for radiation induced transcriptional
targeting with the objective to test the therapeutic effectiveness of the combined radio-gene therapy with p21
promoter driven therapeutic gene interleukin 12.
Methods: To test the inducibility of the p21 promoter, three reporter gene experimental models with green
fluorescent protein (GFP) under the control of p21 promoter were established by gene electrotransfer of plasmid DNA:
stably transfected cells, stably transfected tumors, and transiently transfected muscles. Induction of reporter gene
expression after irradiation was determined using a fluorescence microplate reader in vitro and by non-invasive
fluorescence imaging using fluorescence stereomicroscope in vivo. The antitumor effect of the plasmid encoding the
p21 promoter driven interleukin 12 after radio-gene therapy was determined by tumor growth delay assay and by
quantification of intratumoral and serum levels of interleukin 12 protein and intratumoral concentrations of interleukin
12 mRNA.
Results: Using the reporter gene experimental models, p21 promoter was proven to be inducible with radiation, the
induction was not dose dependent, and it could be re-induced. Furthermore radio-gene therapy with interleukin 12
under control of the p21 promoter had a good antitumor therapeutic effect with the statistically relevant tumor
growth delay, which was comparable to that of the same therapy using a constitutive promoter.
Conclusions: In this study p21 promoter was proven to be a suitable candidate for radiation induced transcriptional
targeting. As a proof of principle the therapeutic value was demonstrated with the radio-inducible interleukin 12
plasmid providing a synergistic antitumor effect to radiotherapy alone, which makes this approach feasible for the
combined treatment with radiotherapy.
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Radiation induced transcriptional targeting is an approach
that uses radiation inducible promoters to achieve spatial
as well as temporal control over transgene expression.
The approach was made possible by the latest improve-
ments in the physical targeting of radiotherapy [1] and
understanding of the molecular mechanisms involved in
the cellular response to ionizing radiation [2,3]. One of
the promoters used for the approach is that of the
CDKN1A gene [4,5], encoding the cyclin-dependent kin-
ase inhibitor 1A protein, more commonly known as p21
or also as WAF1 or Cip1. p21 is a crucial regulator of the
cell cycle, mediating cell cycle G1 phase arrest in response
to stress, and plays a role in cell death, DNA repair, senes-
cence, aging and induced pluripotent stem cells repro-
graming [6]. Promoter of p21 gene can be activated
through p53-dependent [7] and also p53-independent way
by various extrinsic stress stimuli including DNA dam-
aging agents like irradiation and chemotherapeutic drugs,
hypoxia and other intrinsic and oncogene stresses [8,9].
The utilization of p21 promoter for radiation induced
transcriptional targeting was so far confirmed in limited
number of studies, using lipofection of cells and tumors
with plasmids encoding reporter gene GFP and thera-
peutic gene iNOS under the control of p21 promoter
[4,10-12]. Selective transcriptional targeting using the
p21 promoter was demonstrated in an in vitro model of
human microvascular endothelial cells (HMEC-1) and in
an ex vivo rat tail arterial segment model [10]. Further-
more, tumor cell radio-sensitization in vitro and antitu-
mor effectiveness in vivo were proven using different
radiation regimes in murine fibrosarcoma (RIF-1) tu-
mors and human colon adenocarcinoma (HT29) xeno-
grafts [11,12]. Another group demonstrated that p21
promoter driven therapeutic gene herpes simplex virus
type-1 thymidine kinase (HSVtk) transduced by adeno-
associated virus vector in the human breast cancer cells
(MCF-7) can radio-sensitize the cells to repetitive treat-
ment with low dose (1 Gy) irradiation [13].
To date p21 promoter was used in the context of the
suicide gene therapy with therapeutic gens that have local
effect [4,10-13], but lack systemic antitumor effect. One of
the therapeutic genes that has already demonstrated its
systemic radio-sensitizing effect is a gene that encodes for
the secretory protein interleukin 12 (IL-12). IL-12 is a
heterodimeric pro-inflammatory cytokine with multiple
functions, including the induction of interferon-γ (IFN-γ),
activation of T helper and NK cells [14,15], and anti-
angiogenic activity [16-18]. Recombinant IL-12 was pro-
ven to have potent antitumor and antimetastatic effects
against murine tumors [19], yet its clinical application was
hindered by dose-limiting toxicity associated by its sys-
temic administration [20,21]. Systemic treatment was
therefore canceled to be replaced with IL-21 gene therapy,which has already reached the clinical phase [22-24]. To
avoid systemic toxicity clinical trials have been designed
to administer IL-12 directly to the tumor site, for instance
by electroporation of IL-12 plasmid into the metastatic
melanoma lesions [25]. The results of the phase I/II mel-
anoma clinical trial demonstrated [24] the safety of this
approach and also clinical response in the treated and dis-
tant non-treated metastases.
The main aim of our study was to evaluate anti-tumor
effectiveness of combined radio-gene therapy with the
plasmid encoding therapeutic gene Il-12 under the con-
trol of the inducible p21 promoter in a mouse mammary
adenocarcinoma tumor model. For this purpose we first
tested the suitability of the p21 promoter for the radi-
ation induced transcriptional targeting using different
reporter gene experimental models by determining the
induction of expression of reporter gene under the con-
trol of p21 promoter. Specific combination of the p21
inducible promoter and the radio-sensitizing therapeutic
gene Il-12 with radiotherapy has not been tested before.
In addition, clinically used electrotransfer of plasmid
DNA was employed in our study and the study was ex-
tended to another tumor model, mammary carcinoma,
which has not been tested yet by transcriptional target-
ing using p21 promoter. We showed that p21 promoter
is suitable for interleukin 12 radiation induced transcrip-
tional targeting in a mouse mammary adenocarcinoma.
Results
p21 promoter is inducible with irradiation
The suitability of the p21 promoter for the radiation
induced transcriptional targeting was tested using
in vitro and in vivo reporter gene experimental models
(stably transfected cell lines, stably transfected tumors
and transiently transfected muscles). Fluorescence was
determined by fluorescence micro-plate reader in vitro
and by non-invasive fluorescence imaging in vivo and
factors of induction of reporter gene expression after
irradiation were calculated by dividing the fluorescence
obtained in the induced group by the fluorescence in
the control group. Stably transfected cell lines express-
ing the GFP reporter gene under the control of the p21
or a constitutive CMV promoter were successfully prepared
(see methods) and designated as TS/A p21-EGFP and
TS/A CMV-EGFP, respectively. Higher percentage of
GFP expressing cells (95%) was demonstrated by flow
cytometry in TS/A p21-EGFP cell line than in TS/A CMV-
EGFP cell line (70%) (Figure 1). Irradiation of cells with
6 Gy significantly upregulated GFP expression in both
cell lines (p < 0.05) (Figure 2).
Stably transfected tumors were induced in BALB/c mice
by injection of stably transfected TS/A CMV-EGFP and
TS/A p21-EGFP cells. TS/A p21-EGFP tumor model was
used to test dose response of the promoter using tumor
Figure 1 Flow cytometry histograms of GFP expression in (a) TS/A CMV-EGFP and (b) TS/A p21-EGFP cell line.



















































Figure 2 Induction of reporter gene expression in vitro. (a) Fluorescence intensity in TS/A cell lines stably transfected either with p21
(p21-EGFP) or constitutive promoter (CMV-EGFP) driven reporter gene GFP after 6 Gy irradiation (IR). Numbers in the bars are factors of induction
of reporter gene expression or fold-induction, calculated by dividing the fluorescence obtained in the induced group by the fluorescence in the
control group. The data were pooled from three independent experiments performed in 12 replicates and are presented as means + SEM; *,
P < 0.05; NS, non-significant, (b) Visible and fluorescent images and surface plots of the TS/A cells stably transfected with p21 driven reporter gene
GFP after 6 Gy irradiation (IR). On the surface plots fluorescence intensities are represented linearly on a rainbow scale with red being the
maximum signal and black being the lowest signal.
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that the induction was not dose dependent, since the dose
of 6 Gy induced higher reporter gene expression than dose
of 10 Gy. Increase in fluorescence intensity was the highest
and statistically significant compared to the control group
(p < 0.05), on the third day after 6 Gy irradiation by a fac-
tor of 1.16× (Figure 3). The activity of p21 promoter was
compared to the activity of the constitutive CMV pro-
moter in the stably transfected TS/A CMV-EGFP tumor
model. The activity of both promoters after 6 Gy irra-
diation was very similar; the induction of p21 promoter
was slightly more rapid and higher, but the differences
were not statistically significant (p > 0.05) (Figure 3).
Model of transiently transfected muscles was used to test







































Figure 3 Induction of reporter gene expression in vivo (tumors). (a) B
TS/A p21-EGFP tumor model with reporter gene GFP under the control of
tumor model with reporter gene under the control of CMV promoter after
in arbitrary units and is normalized on the day 0 and on the appropriate co
tumors and for the CMV on the non-irradiated TS/A CMV-EGFP tumors. The
in each experimental group and are presented as means + SEM; *, P < 0.05
dynamics of the inducible p21 and constitutive CMV promoter after 6 Gy ir
control group and experimental group that received 6 Gy irradiation (IR). F
red being the maximum signal and black being the lowest signal.and if promoter can be re-induced. Muscle irradiation
with 6 Gy one day after the gene electrotransfer with plas-
mid p21-EGFP activated the reporter gene, but the induc-
tion was not statistically significant (p > 0.05), though
significant increase in reporter gene expression (1.2×,
p < 0.05) was obtained with the repeated muscle irradi-
ation, 7 days after the first, providing evidence of reporter
gene re-induction (Figure 4).
Radio-gene therapy with inducible Il-12 plasmid has a
synergistic therapeutic effect
To determine the therapeutic effect of combined radio-
gene therapy, TS/A tumors were transfected with plasmids
encoding p21 or constitutive promoter-driven Il-12, using
















ar chart: normalized fluorescence intensity in the stably transfected
p21 promoter after 0, 2, 6 and 10 Gy irradiation, and in TS/A CMV-EGFP
6 Gy irradiation. For all experimental groups fluorescence is expressed
ntrols: for the p21 promoter on the non-irradiated TS/A p21-EGFP
data were pooled from 2 independent experiments with 4–5 animals
vs. control; NS, non-significant. Line plot: comparison of the induction
radiation. (b) Images of stably transfected TS/A p21-EGFP tumors in
luorescence intensities are represented linearly on a rainbow scale with







































Figure 4 Induction of reporter gene expression in vivo (muscles). (a) Bar chart: normalized fluorescence in the mouse muscles transiently
transfected with the plasmid carrying reporter gene GFP under the control of p21 promoter after 6 Gy irradiation on day 1 and day 8 after gene
electrotransfer (GET) of p21-EGFP plasmid. For all experimental groups fluorescence is normalized on the day 0 and is expressed in arbitrary units.
The data were pooled from 2 independent experiments with 7–8 animals in each experimental group and are presented as means + SEM; *,
P < 0.05 vs. control. Line plot: induction dynamics of the p21 promoter after 6 Gy irradiation on day 1 and day 8 after gene electrotransfer (GET).
(b) Images of mouse legs in control group and experimental group that received 6 Gy irradiation on day 1 and day 8 after the transfection with
plasmid p21-EGFP (IR 1 + 8). Fluorescence intensities are represented linearly on a rainbow scale with red being the maximum signal and black
being the lowest signal.
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blood were collected 5 days after the irradiation to deter-
mine intratumoral and serum levels of IL-12 protein and
intratumoral concentrations of Il-12 mRNA.
Antitumor effect of radio-gene therapy with Il-12 under
control of the inducible p21 promoter was comparable to
effect of the same therapy using a constitutive promoter.
Tumor growth delay was statistically significantly longer,
compared to control group, in both experimental groups
that received radio-gene therapy with inducible and con-
stitutive IL-12 plasmids (p < 0.05) (Figure 5). Although the
growth delay was longer in the group with the constitutive
promoter (18.2 days) than in the group with inducible
promoter (14.4 days) the difference was not statistically
significant (p > 0.05). All other pertinent control groups
did not result in significantly prolonged growth delays,compared to the untreated control group. The growth
delays in both therapeutic groups (receiving radio-gene
therapy with inducible or constitutive IL-12 plasmids)
were longer than the sum of radio- (0.7) and gene-
monotherapies (3.45), indicating that the effect of com-
bined therapy was synergistic. The synergistic effect was
also confirmed by criteria for assessment of combined ef-
fect of two therapies with independent mechanisms of ac-
tion [26]. Furthermore, tumor cures were obtained after
radio-gene therapy using both plasmids.
Intratumoral and serum concentrations of IL-12 pro-
tein, as well as Il-12 mRNA, were statistically signifi-
cantly elevated in the group that received radio-gene
therapy with the constitutive pORF-mIL-12 plasmid
(Figure 5). Furthermore, serum concentrations were sta-











































































































































































DT (days) GD (days) CR(n) N
Control 3.03±0.25 0 0 18
EP 2.88±0.40 -0.15±0.40 0 12
IR 3.75±0.38 0.73±0.38 0 10
EP+IR 4.52±1.00 1.50±1.00 0 10
p21 3.86±0.50 0.83±0.50 0 12
p21+EP 6.47±0.94 3.45±0.94 0 16
p21+IR 5.67±1.96 2.64±1.96 0 10
p21+EP+IR 17.45±5.84 14.41±5.84* 1 (8.3%) 12
pORF 4.29±0.44 1.26±0.44 0 12
pORF+EP 5.63±1.19 2.60±3.58 1 (6.7%) 15
pORF+IR 3.93±0.61 0.90±0.61 0 10
pORF+EP+IR 23.00±7.18 18.20±7.04* 3 (25%) 12
Time (days)







































Figure 5 Therapeutic effect of radioinducible IL-12 gene therapy after 6 Gy irradiation in mouse TS/A tumors. EP, electroporation; IR,
irradiation; p21, intratumoral injection of the p21-mIL-12 plasmid; p21 + EP, gene electrotransfer of the p21-mIL-12 plasmid; p21 + EP + IR,
radio-gene therapy with the p21-mIL-12 plasmid; pORF, intratumoral injection of the pORF-mIL-12 plasmid, pORF + EP, gene electrotransfer of
the pORF-mIL-12 plasmid; etc. (a) DT, doubling time i.e. time needed for the tumor to double in size; GD, growth delay i.e. difference between
the doubling time of the specific experimental group and average doubling time of the control groups); CR, complete response i.e. complete
disappearance of the tumor lasting for 100 days; N, number of the animals in the individual experimental group; data are presented as mean ± SEM;*,
P < 0.05 vs. control. (b) Tumor growth curves after radioinducible IL-12 gene therapy. The data were pooled from 2 independent experiments with
18–10 animals in each experimental group and are presented as means with the standard errors of the mean. (c) Serum and (d) intratumoral IL-12
protein concentrations and (e) intratumoral Il-12 mRNA levels on the 5th day after the induction with irradiation. Each column represents mean + SEM.
(c) *, P < 0.05 vs. control, 6–9 animals per experimental group. (d) *, P < 0.05 vs. all experimental groups except pORF + EP, 2–3
animals per experimental group. (e) *, P < 0.05 vs. control, 2–3 animals per experimental group.
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irradiation. Elevated serum concentrations were also ap-
parent, but not statistically significant, after GET of in-
ducible plasmid p21-mIL-12, especially in combination
with irradiation.
Discussion
To improve the efficacy and safety of gene therapy spatial
and temporal regulation of therapeutic gene is needed. This
kind of regulation is especially important for the clinical ap-
plication of gene therapy to achieve a sustained therapeutic
level of transgene product without systemic toxicity andalso to be able to adjust the transgene expression according
to the stage of disease. Although gene therapy is becoming
a realistic alternative modality for treatment of cancer with
clinical trials underway [27], it is not very likely that it will
be used as a monotherapy. If gene therapy is combined
with radiotherapy, a well-established cancer treatment, in-
ducible promoters can be used to gain more controlled
transgene expression in an approach called radiation in-
duced transcriptional targeting.
In the first part of our study, the feasibility of the p21
promoter for inducible therapy was tested using in vitro
and in vivo reporter gene experimental models with GFP.
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the dose response of the p21 promoter in vivo was based
on established radiobiology protocols [28]. Reporter gene
experimental models were prepared by stable transfection
of the tumor cells to ensure higher and more uniform
gene expression (standardized conditions) enabling more
reproducible data and lower intra- and inter- variability
among experimental groups. This experimental setup was
also established to comply with 3Rs’ rule in animal ex-
perimentation (EU directive 2010/63/EU). Furthermore,
established experimental models enabled us to determine
the activity of promoters by simply quantifying the fluor-
escence intensity, presuming that fluorescence is propor-
tional to gene expression that is proportional to the
activity of the upstream promoter. Interestingly, in a simi-
lar study also using p21 promoter driven GFP reporter
gene [10], expression was determined with a semi quanti-
tative Western blot method, instead of fluorescence inten-
sity. The induction factors after radiation were relatively
low compared to factors obtained in that study [10]. How-
ever, similar to our results, the induction factor was the
highest after the irradiation with 6 Gy [10], which is in
agreement with our dose response experiment on stably
transfected tumors. The reason for low induction factors
in our study could be that in our study a cancer cell line
(TS/A) was used and cancer cell lines in general have high
basal level activity of p21 promoter, compared to non-
cancer cell lines, with characteristically low basal level
activity [4]. Namely, the induction factors appear to be
different for different cell lines; the differences are espe-
cially apparent between normal and cancer cell lines [4].
Already during the preparation of the stable cell line with
p21 promoter we noticed that basal activity of the p21
promoter was relatively high as it was easily seen under
the fluorescence microscope, and was comparable to the
intensity in cell lines with CMV promoter. Generally, high
basal activity is an unwanted characteristic in an inducible
promoter. Nevertheless, if p21 promoter is to be used in
cancer therapy, this selectiveness is an advantage and not
hindrance because it enables selective targeting of cancer
cells, which could be highly beneficial.
Another, already proven and potentially beneficial, char-
acteristic of p21 promoter is that it can be induced by
hypoxia [12] which is a physiological feature of almost all
solid tumors [29]. Hypoxia remains a great hindrance for
radiotherapy, since oxygen is essential for generation of
ROS that are responsible for therapeutic efficacy of irradi-
ation [30,31]. The physiological difference in the oxygen-
ation can, on the other hand, be exploited for more
selective cancer therapy with the use of hypoxia inducible
promoters [32]. Since hypoxia inducible gene therapy re-
lies on the lack of oxygen and radioinducible therapy
needs the production of oxygen derived free radical, nei-
ther approach is adequate for the treatment of the wholetumor. Vectors containing synthetic promoters responsible
to both stimuli have therefore been developed [33]. These
so called chimeric promoters that contain an optimal num-
ber and arrangement of responsive elements derived from
different hypoxia and radioinducible promoters were ini-
tially introduced in 2002 [34]. In the more advanced of the
chimeric promoters the control over the expression of
transgene moves from the inducible to a strong constitutive
promoter after the initial signal in order to ensure higher
level of expression [35]. In addition to this so called “mo-
lecular amplification switch” vectors with these promoters
also have to contain a so called “stop cassette”, that halts
the expression of the transgene in the absence of a stimuli
[36]. Although p21 promoter is a simple native promoter
of a gene that is present in all human cells, it can be
matched-up with these sophisticated synthetic promoters
because it has similar characteristics: it is induced by hyp-
oxia and irradiation, it has a high basal activity that is lim-
ited to tumor cells, and after the removal of a stimuli its
activity in normal cell falls again to the basal level, but re-
mains high in tumor cell.
In our study the activity of inducible p21 promoter
was compared to the activity of the CMV promoter
which is a standard promoter used in many gene therapy
studies [37], although we were fully aware of its draw-
backs. Namely, we demonstrated that CMV promoter
was also induced after irradiation: in vitro the induction
was even higher in the cell line with CMV promoter
than in cell line with p21 promoter, although the differ-
ence was not statistically significant. In vivo we also
showed that the induction dynamics were similar in both
inducible p21 and constitutive CMV promoter; the in-
duction of p21 promoter was slightly faster and more
pronounced but the difference was not statistically sig-
nificant. We tackled the problem of the non-constitutive
nature of CMV promoter in a separate study, where we
showed that CMV promoter indeed gets activated after
irradiation, which limits its usefulness as a constitutive
promoter [38].
At the end of reporter genes part of the study we
wanted to check if p21 promoter is suitable for inducible
therapy also after transient transfection, since this kind of
therapy is more appropriate for clinical use of gene ther-
apy. For the model, transiently transfected muscles model
was chosen, because it allows better detection of fluores-
cent reporter gene detection then the tumor model. In
addition to higher transfection efficiency, longer lasting
transfection is characteristic for skeletal muscles, therefore
reinducibility of p21 promoter could be determined. This
could not be done on stably transfected tumors or tumor
cells because of their short life span due to the fast growth
rate of cells and tumors. Skeletal muscle was proven in
the past as a good tissue for electrically assisted gene
transfer [39-41]. We demonstrated that p21 promoter can
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muscles; deducted from the level of expression after the
first and the second induction alone, the combined induc-
tion was the sum of both. To our best knowledge this is
the first time p21 promoter was used in a similar experi-
ment and proved that it is suitable for transcriptional tar-
geting after transient transfer in the muscle tissue.
In the second part of the study the therapeutic effect-
iveness of the combined radio-gene therapy with p21
promoter controlling the expression of the therapeutic
gene Il-12 was evaluated in a relatively radioresistant
and IL-12 resistant TS/A tumor model [42,43]. The radi-
ation induced transcriptional targeting approach allows
for any therapeutic gene with radiosensitizing properties
to be chosen. One of the therapeutic genes that has
already demonstrated its radio-sensitizing effect is IL-12
[44-52]. Although not fully elucidated, proposed mecha-
nisms of IL-12 radio-sensitization were enhanced tumor
antigen presentation due to radiation induced apoptosis
[49], anti-angiogenic effects [42], and the production of
radiosensitizer nitric oxide [52]. In addition to potent
local radio-sensitizing activity [44-52], IL-12 gene ther-
apy can also offer the systemic protection against distant
metastases by induction of an effective immune response
against tumor antigens or inhibiting angiogenesis of me-
tastases [21,24,25,53].
The results of this part of our study showed that
radio-gene therapy with Il-12 under control of the indu-
cible p21 promoter had a good antitumor effect that
was comparable to that of the same therapy using a
constitutive promoter. Furthermore, the effect of com-
bined therapy proved to be synergistic to both radio-
and gene- therapy. Synergistic working of IL-12 and ir-
radiation was reported before in a number of preclinical
studies combining local or systemic (through systemic
IL-12 release from the transfected muscle) IL-12 gene
therapy with local irradiation in several different murine
tumors [44-48]. In one such study, that is perhaps the
most similar to ours, a plasmid in which the expression
of IL-12 was controlled by the inducible Egr1 promoter
was used in the B16 murine tumor model [54]. The sub-
cutaneous tumors were injected with naked plasmid
DNA and 24 later exposed to 2 and 5 Gy irradiation
and this treatment protocol was then repeated 3-times
per day every second day. The result was a statistically
relevant tumor growth delay and elevated intratumoral
IL-12 level in the group that received this triple radio-
gene therapy compared to the control group.
Although therapeutic effect of radio-gene therapy with
the inducible p21 promoter was comparable to that of the
same therapy using the constitutive promoter, serum and
intratumoral concentrations of IL-12 and intratumoral Il-
12 mRNA levels were significantly lower after radio-gene
therapy with p21 promoter then after radio-gene therapywith the constitutive promoter. Lack of correlation be-
tween serum and tumoral levels of IL-12 and antitumor
effect was also observed in previous studies. Specifically,
the levels of IL-12 vary significantly among different ex-
periments and different mouse models indicating that the
therapeutic effect of the IL-12 gene therapy cannot be dir-
ectly linked to the IL-12 protein or mRNA levels
[47,55,56]. Moreover, elevated levels may not even be pre-
requisite for the therapeutic effect [56]. Another possible
reason for the observed difference in our study could be
that we determined the levels at day 5 after radio gene
[47]. Since the therapeutic effect of both constitutive and
p21 plasmids were similar, we assume that we probably
missed the peak of Il-12 expression in p21 group. This is
also supported by the results of the reporter gene part of
our study, where we showed that the expression of GFP
controlled by p21 promoter was the highest on the third
day after induction with irradiation. Considering that
GFP’s half-time [57] is noticeably longer than IL-12-s half-
time [58], we speculate that peak in Il-12 expression after
radio gene therapy with p21 promoter occurred before
the measurements.
Based on the results of this preclinical study showing
that p21 promoter has a similar effectiveness as the con-
stitutive promoter, we trust it is suitable for further deve-
lopment. Namely, general tendency in gene therapy is to
replace virus derived promoters with endogenous pro-
moters, due to the safety concerns and longer lasting
expression they support [37]. Therefore, p21, as an en-
dogenous promoter with low basal activity in normal cells,
higher activity in cancer cells and inducibility by different
treatment induced stresses, is a prospective candidate for
translational studies in cancer gene therapy.
Conclusions
In this study we demonstrated, using the reporter gene
experimental models, that p21 promoter is a feasible can-
didate for radiation induced transcriptional targeting. As a
proof of principle, the combined radio-gene therapy with
inducible Il-12 plasmid was demonstrated to have a syner-
gistic therapeutic effect to radio and gene-monotherapies,
making this approach feasible for the combined treatment
with radiotherapy, which, we believe, is crucial for transla-
tion of this approach into the clinical setting.
Methods
Plasmids
Two commercial available plasmids were used: a plasmid
encoding green fluorescence protein (GFP) under the
control of the strong constitutive human cytomegalo-
virus (CMV) immediate early promoter and neomycin
resistance gene (pEGFP-N1, Clontech, Basingstoke, UK)
and a plasmid encoding mouse Il-12 under the control
of a constitutive hybrid promoter EF-1α/HTLV (pORF-
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p21 promoter sequence was a plasmid encoding GFP under
the control of the human p21 promoter (and neomycin re-
sistance gene) (p21-EGFP) which was a kind gift from Irena
Hreljac, (National Institute of Biology, Ljubljana, Slovenia).
Eukaryotic expression plasmid encoding the therapeutic
gene Il-12 under the control of p21 promoter (p21-mIL-12)
was prepared from plasmids p21-EGFP and pORF-mIL-12
using standard molecular-biological methods of restriction
and ligation: first the reporter gene GFP was cut out of
the plasmid p21-EGFP by the restriction enzymes SalI and
XbaI and was then replaced with the therapeutic gene
Il-12, which was cut out of the plasmid pORF-mIL-12 using
the compatible restriction enzymes SalI and NheI. For the
experiments plasmid DNAs were isolated using the Endo-
Free Plasmid Mega Kit (Qiagene, Hilden, Germany) accord-
ing to manufacturer’s instructions and diluted in endotoxin
free water to a concentration of 1 mg/ml. Plasmid DNA
concentration and pureness was determined spectrophoto-
metrically and by gel electrophoresis.
Cell lines and experimental animals
Murine adenocarcinoma of the mammary glands TS/A
[41] cell line was used in the experiments. During the
in vitro experiments, cells were maintained in Eagle’s
minimum essential medium (EMEM, Sigma, Taufkirchen,
Germany), supplemented with 10% fetal calf serum (FCS,
Sigma, Taufkirchen, Germany), 2 mM L-glutamine (Gibco
Invitrogen, San Diego, California, USA) and 100 IU/ml
penicillin/streptomycin (Pliva, Zagreb, Croatia) in a hu-
midified incubator at 37°C with 5% CO2.
For the in vivo experiments, female BALB/c and C57BL/
6 mice obtained from the Institute of Pathology, Faculty of
Medicine, University of Ljubljana, Slovenia, were used. At
the beginning of the experiments, the animals were 10–
12 weeks old. Mice were housed and maintained in a
specific pathogen-free animal colony at constant room
temperature (21°C) and 12 h light/dark cycle. Food and
water was provided ad libitum. Animals were subjected to
an adaptation period of 7–10 days before the experiments
were carried out. All procedures on animals were per-
formed in accordance with the official guidelines of the
EU directive (2010/63/EU) and with the permission of the
Ministry of Agriculture and environment of the Republic
of Slovenia (permission No.: 323-02-632/2005/6).
Reporter gene experimental models
Stable cell lines
TS/A cells were transfected with the p21-EGFP (containing
the p21 promoter) and pEGFP-N1 (containing the CMV
promoter) plasmids. Electroporation was used for introduc-
tion of plasmid DNA into cells. Specifically, cells grown as
a monolayer were harvested and a 2.5 × 107 cells/ml
cell suspension was prepared in electroporation buffer(125 mM sucrose, 10 mM K2HPO4, 2.5 mM KH2PO4,
2 mM MgCl2 × 6 H2O). A dense cell suspension with a
concentration of 1 × 106 cells and 10 μg of pEGFP-N1 in
50 μl of electroporation buffer was placed between two flat
parallel stainless steel electrodes with a 2 mm gap con-
nected to the GT-1 electroporator (University of Ljubljana,
Faculty of Electrical Engineering, Ljubljana, Slovenia) and
subjected to eight square-wave electric pulses with an amp-
litude per distance ratio 700 V/cm, 5 ms duration time and
1 Hz repetition frequency. After electroporation cells were
incubated for 5 min at room temperature, plated into
Petri dishes and then cultured for two months under in-
creasing concentrations (1200–2000 μg/ml) of the se-
lection agent geneticin (Gibco Invitrogen, San Diego,
California, USA) to obtain resistant clones. Clones with
the highest GFP expression were identified by fluores-
cence microscopy (Olympus, Hamburg, Germany), iso-
lated, propagated and frozen in liquid nitrogen for
subsequent experiments. To determine the number of
fluorescent cells, flow cytometry analysis of stable cell
lines carrying p21 and CMV promoter-driven reporter
gene constructs was performed: cells were trypsinized,
collected and 2 × 104 cells from each stable cell line
were analyzed using flow cytometry (Becton Dickinson,
Calibur, Franklin Lakes, USA) by determining the per-
centage of EGFP-positive (fluorescent) cells and median
fluorescence intensity of the EGFP (Figure 1). Laser ex-
citation was 488 nm and number of events was 20.000.
Stably transfected tumors
2 × 106 viable TS/A CMV-EGFP and TS/A p21-EGFP
tumor cells prepared from cell cultures in vitro were
injected dorsolaterally in BALB/c mice for the induction
of solid subcutaneous tumors. When the tumors reached
approximately 40 mm3 in volume (7–10 days), mice were
randomly divided into experimental groups and subjected
to a specific experimental protocol.
Transiently transfected muscles
C57Bl/6 mice were anaesthetized with isofluran (Torrex
Chiesi GmbH, Wien, Austria) using an isoflurane vaporizer
(Datex Ohmeda, Helsinki, Finland). Plasmid pEGFP-N1
(20 μg in 20 μl of water) was injected into both right and
left musculus tibialis cranialis with a thin (26 G) needle.
The hind legs were placed between two flat parallel stain-
less steel electrodes with rounded corners (dimensions
20 mm× 10 mm) with a 6 mm gap between the electrodes
connected to the electric pulse generator Cliniporator™
(IGEA s.r.l., Carpi, Italy), and subjected to one high-voltage
square-wave electric pulse with an amplitude per distance
600 V/cm and 100 μs duration and 4 low-voltage square-
wave electric pulses with an amplitude per distance
80 V/cm, 100 ms duration and 1 Hz repetition frequency.
Good contact between the electrodes and legs was assured
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Krka, d.d., Novo mesto, Slovenia) and use of a con-
ductive gel (Kameleon d.o.o., Maribor, Slovenia). A day
after gene electrotransfer, mice were randomly divided
into experimental groups and subjected to a specific
experimental protocol.
Irradiation
Cells, tumor-bearing BALB/c mice and C57BL/6 mice
with transiently transfected muscles were irradiated
using an X-ray unit Darpac 2000 (Gulmay Medical Ltd,
Shepperton, UK) operating at 220 kV, 10 mA, and with
0.55 mm Cu and 1.8 mm Al filtration. Stably transfected
cells were plated at a density of 1.7× 104 cells/cm2 and
were irradiated with single dose of 6 Gy. Mice with stably
transfected tumors were irradiated with 2, 6 and 10 Gy
and mice with transiently transfected muscles were irradi-
ated with the dose of 6 Gy at day 1 and day 8 after the
gene electrotransfer. During irradiation, mice were re-
strained in special lead holders with apertures for irradi-
ation of the tumors/legs, exposing only the tumors/legs
and shielding the rest of the body from irradiation.
Quantification of reporter gene expression
In vitro: Three days after the treatments, cells were
trypsinized, collected and 2 × 105 cells were plated in
96-well microplates. Expression of the reporter gene was
followed using the fluorescence microscopy (Olympus,
Hamburg, Germany) and determined using the fluores-
cence microplate reader Infinite 200 (Tecan, Männedorf,
Switzerland). Induction factors i.e. factors of induction
of reporter gene expression after irradiation were calcu-
lated as quotients between induced and control group.
In vivo non-invasive fluorescence imaging: After the
treatments, fluorescence intensity of the tumors and mus-
cles expressing GFP was followed transcutaneously using
a fluorescence stereo microscope (Lemar.V.12., Zeiss,
Jena, Germany), which enabled non-invasive follow-up of
the intensity and duration of GFP expression. At each ob-
servation under the microscope, hair over the tumor or
muscle was removed using an electric shaver and hair
removal cream and animals were anaesthetized with iso-
flurane as described above. Digital images of fluorescence
were recorded everyday post-treatment for 8 days for tu-
mors and every 2–3 days for 12 days in the case of the
muscle with a digital color camera (Axiocam MRc5, Zeiss,
Jena, Germany) connected to the fluorescence stereo
microscope. During capture, tumors or legs were placed
in a special holder to minimize the movement of animals
caused by breathing and to ensure the same positioning at
each observation.
Fluorescent image of the tumor with stably transfected
tumor cells and muscle fibers fluorescing through the skin
were analyzed using the ImageJ software tool (NationalInstitute of Mental Health, Research Services Branch,
Bethesda, Maryland, USA). Images of the same tumor
or muscle taken at different time points were stacked
together. Fluorescence of the tumor cell or muscle fi-
bers was separated from the background fluorescence
using the threshold tool and mean grey value i.e. intensity
of the area under threshold was determined. Adjusted
mean fluorescence intensity of each tumor or muscle slice
in the stack was then normalized to the mean fluorescence
intensity at day 0.
Radio-gene therapy
Radio-gene therapy was performed in two steps consist-
ing of gene electrotransfer to tumors followed by irradi-
ation. For the execution of gene electrotransfer, the
tumors were first injected with 50 μg of plasmid DNA
(p21-mIL-12 or pORF-mIL-12) in 50 μl of sterile water
and 10 minutes later subjected to 8 square-wave electric
pulse with amplitude per distance 600 V/cm and 5 ms
duration with 1 Hz repetition frequency. Good contact
between the electrodes and tumor was assured by hair
removal using electric shaver and use of a conductive gel
(Kameleon d.o.o., Maribor, Slovenia). Twenty-four hours
later tumors were irradiated with a dose of 6 Gy as de-
scribed above.
Determination of therapeutic effect
The therapeutic effect of radio-gene therapy was deter-
mined using the tumor growth delay assay. Tumors were
measured in three perpendicular directions (a, b, c) every
2–3 days using a digital caliper. Tumor volume was calcu-
lated by the formula: V = a × b × c × π/6. Tumor growth
was followed until tumors reached average volume of
350 mm3, and then the animals were sacrificed. Animals
with tumors in regression were examined weekly for the
presence of the tumor for 15 consecutive weeks. The ani-
mals were considered cured if they were tumor-free at day
100. Doubling time (DT) or tripling time (TT) for each
tumor was determined as the time when tumors reached
double or triple the volume on day 0, respectively, and
was expressed in days. Growth delay (GD) for each ex-
perimental group was determined as the difference be-
tween DT or TT of the experimental group and DT or
TT of the control group.
Tumors and blood collection for Enzyme-Linked Immuno-
Sorbent Assay (ELISA) and Real Time Polymerase Chain
Reaction (qPCR)
Tumors and blood samples were collected from individual
mice from each experimental group at day 5 post-
treatment. Blood was collected from the intraorbital sinus
into collection tubes and stored at room temperature for
2 hours. Serum was extracted from blood samples by cen-
trifugation at 3,000 rpm for 5 min and immediately stored
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was collected mice were sacrificed and tumors were re-
moved, weighed and stored at −80°C. Frozen tumors were
mechanically macerated in liquid nitrogen. For the ELISA
test, tumor samples were diluted with 500 μl of PBS con-
taining protease inhibitors (Protease Inhibitor Cocktail,
phenylmethylsulfonyl fluoride (PMSF) and Sodium
Orthovanadate, all Santa Cruz Biotechnology, Inc.,
Heidelberg, Germany, 10 μl of each per ml of PBS),
thoroughly mixed and centrifuged for 10 min at
10,000 rpm. The supernatant was separated from the
sediment and stored at −80°C until analysis. Both sets
of samples (serums and supernatants from the tumor
tissue) were analyzed using ELISA Quantikine Mouse
IL-12 p70 Immunoassay (R&D Systems, Minneapolis,
MN, USA) for detection of IL-12. Concentrations of IL-
12 were calculated as pg of cytokine per ml of serum or
ng of cytokine per mg of tumor tissue.
For the qPCR total RNA was extracted from frozen tu-
mors using TRIzol Plus RNA Purification Kit (Invitrogen)
according to the manufacturer’s instructions. The RNA
concentrations were quantified by spectrophotometer at
260 nm. A 1 μg of total RNA was reverse transcribed into
complementary DNA using SuperScript VILO cDNA
Synthesis Kit (Invitrogen), according to manufacturer’s in-
structions. After reverse transcription, 2 μl of the 10-times
and 100-times diluted mixture was used as the template
for the following QPCR using TaqMan Gene Expression
Master mix (Applied Biosystems) and TaqMan Gene
Expression Assay (Applied Biosystems). TaqMan Gene
Expression Assay contained pair of primers and Taq-
Man MGB probe (ID: Mm00434165_m1) to amplify the
alpha subunit of IL-12 and TaqMan MGB probe (ID:
Mm00446968_m1) to amplify the housekeeping gene
hypoxanthine-guanine phosphoribosyltransferase (Hprt1),
which was used as a reference gene. A total of 50 cycles of
PCR was performed as follows: activation of AmpliTaq
Gold Enzyme (10 min at 95°C), denaturation (15 s at 95°C),
annealing and extension (1 min 60°C). The PCR prod-
ucts were analysed using 7300 System SDS software
V.1.3.1 (Applied Biosystems). The level of Il-12 expres-
sion in each sample was calculated as ratio of Il-12 vs.
reference gene Hprt1 RNA and normalized to untreated
control group.
Statistical analysis
Statistical analysis was performed using SigmaPlot 12.0
(Systat Software Inc., San Jose, CA, USA). The data were
tested for normality of distribution using the Shapiro-Wilk
test. Differences between independent experimental groups
were statistically evaluated by the Student’s t test and differ-
ences between dependent experimental groups by one-way
analysis of variance (one-way ANOVA). A P value of less
than 0.05 was considered to be statistically significant. Thesynergistic effect between treatments was determined by
criteria for assessment of combined effect of two therapies
with independent mechanisms of action [26].
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